Shares of 4d Pharma PLC (LON: DDDD) fell 3.25% despite the biotech company announcing that it will participate in the 5th Microbiome Movement Drug Development Summit Europe to be held on 28 January 2021.
The stock continues to trade within a tight range that has been in place since the start of January due to the lack of major announcements from the company, which specialises in the development of Live Biotherapeutic products (LBPs).
4D Pharma told investors yesterday that it is still on track to complete its merger with Longevity Acquisition Corporation (NASDAQ: LOAC), a publicly-traded special purpose acquisition company in Q1 depending on when the US Securities & Exchange Commission (SEC) will complete its review.
The company is a world leader in the development of live bio-therapeutics based on the over 1000 patents the company has been granted globally for its top treatments targeting cancer, asthma and is way ahead of its few competitors.
4D Pharma has several treatments such as its MRx0518 solid tumors treatment in combination with Keytruda and its Blautix irritable bowel syndrome drug in phase 2 trials. Investors are looking forward to these drugs entering phase 3 trials in the near future.
The live biotherapeutics company has other drugs in phase 1 and others in the development and preclinical stages, which could become successful treatments in future. Any major announcements from the company could trigger a large move in either direction.
Investors who believe in the company’s future prospects may find that now is a great time to establish a position in the company to benefit from any future gains given that the stock has been stuck trading sideways for a while.*
*This is not investment advice.
4d Pharma share price
4D Pharma shares fell 3.25% to trade at 119p having dropped from Tuesday’s closing price of 123p.
